Zomepirac
Zomepirac is a nonsteroidal anti-inflammatory drug (NSAID) that was introduced in the early 1980s under the brand name Zomax. It was primarily used for its analgesic properties to relieve moderate to severe pain. Despite its effectiveness, the use of Zomepirac was associated with serious adverse effects, leading to its withdrawal from the market.
Pharmacology[edit | edit source]
Zomepirac functions by inhibiting the enzyme cyclooxygenase (COX), which is essential in the biosynthesis of prostaglandins. Prostaglandins are lipid compounds that play a key role in inflammation, pain, and fever. By reducing the production of prostaglandins, Zomepirac effectively alleviates pain and reduces inflammation.
Clinical Use[edit | edit source]
Zomepirac was indicated for the management of acute pain conditions. Its potency and ability to provide significant pain relief made it a popular choice for post-operative pain, as well as for conditions such as arthritis and other musculoskeletal disorders.
Adverse Effects[edit | edit source]
The use of Zomepirac was associated with several adverse effects, the most serious being an increased risk of anaphylaxis. Anaphylaxis is a severe, potentially life-threatening allergic reaction that can occur rapidly. Other side effects included gastrointestinal issues, such as ulcers and bleeding, as well as renal impairment.
Market Withdrawal[edit | edit source]
Due to the risk of severe allergic reactions, Zomepirac was withdrawn from the market in 1983. The decision to remove the drug was based on the accumulation of reports indicating a higher than acceptable risk of anaphylaxis among users. The withdrawal of Zomepirac highlights the importance of post-marketing surveillance in the pharmaceutical industry, ensuring that the benefits of a drug outweigh its risks.
Legacy[edit | edit source]
The withdrawal of Zomepirac serves as a case study in drug safety and pharmacovigilance. It underscores the necessity for ongoing monitoring of drugs after they have been approved and introduced to the market. The case of Zomepirac also emphasizes the importance of patient education regarding the potential risks associated with medication use.
See Also[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
